• Syed Asif J Kazmi
  • Moosa Khan
  • Ghulam Rasool Mashori
  • Azra Saleem
  • Naheed Akhtar
  • Ashraf Jahangeer


Background: The correlations between combined body fat parameters and risk factors of obesityexplained a portion of the variation in the weight, BMI and waist circumference, the averagenumber of categorical metabolic risk factors increases progressively with increasing total body fatcontent. There is currently no data available in which influence of drugs can be assessed on totalbody fat content. This was a non-randomized, prospective, open-label, parallel group study wasconducted to compare the effectiveness of sibutramine, orlistat and ispahgula in reducing bodyweight and percentage of total body fat content in obese individuals. Methods: A nonrandomized,open label, prospective, intention to treat clinical trial was conducted from July 2008 to March2009 in JPMC, Karachi, Pakistan. The study was based on three arms A (ispahgula), B (orlistat)and C (sibutramine) comprising 40 patients in each. The selection criteria has included patientsfrom either sex with age 18 years or more with BMI ≥30 as obese with or without associated riskfactors and BMI ≥27 <30 as over weight only if any significant risk factor is present. Complianceon diet chart and instruction for life style modification were assessed monthly. Results: Thecomparison of mean difference in percentage of total body fat content between the groups andwithin the groups at day 150 is (p-value) 0.029 and difference in body weight is (p-value) 0.042which is statistically significant. Conclusion: Sibutramine is more effective than ispahgula andorlistat in reducing body weight and percentage of total body fat content in obese patients.Keywords: Sibutramine, Orlistat, Ispahgula, body weight and obesity.


Rucker D, Padwal R, Li SK, Curioni C, Lau DC. Long term

pharmacotherapy for obesity and overweight: updated metaanalysis, BMJ 2007;335:1194–9.

Ford ES, Giles WH, Mokdad AH, Increasing prevalence of

metabolic syndrome among US Adults. Diabetes Care


McDermott AY. Conference coverage: 20th Annual Practical

Approaches to the Treatment of Obesity. Med Gen Med

Published online 2006;8(4):61.

Rehman T, Rizvi Z, Siddiqui U, Ahmad S, Sophie A,

Siddiqui M, et al. Obesity in Aldolescent of Pakistan. J Pak

Med Assoc 2003;53:315.

Seidell JC, Flegal KM. Assessing obesity classification and

epidermiology. Br Med Bull 1997;53(2):238–52.

Sjostrom L, Lindroos AK, Peltonen M, Torgerson J,

Bouchard C, Carlsson B, et al. Lifestyle, diabetes and

cardiovascular risk factors 10 years after bariatric surgery, N

Engl J Med 2004;351(26):2683–93.

Nammi S, Saisudha K, Chinnala KM, Boni KM. Obesity: an

overview on its current perspectives and treatment option.

Nutrition Journal 2004;14(3):3.

Carrière F, Renou C, Ransac S, Lopez V, De Caro J, Ferrato

F, et al. Inhibition of gastrointestinal lipolysis by Orlistat

during digestion of test meals in healthy volunteers.. Am J

Physiol Gastrointest Liver Physiol 2001;281:G16–28.

Guerciolini R, Mode of action of orlistat. Int J Obes Relat

Metab Disord 1997;21(Suppl 3):S12–23.

Bergmann JF, Chassany O, Petit A, Triki R, Caulin C,

Segrestaa JM. Correlation between echographic gastric

emptying and appetite: influence of psyllium. Gut


Feigenbaun A, Pasternak S, Zusk E Sarid M, Vinker S.

Influence of multidisciplinary follow-up and orlistat on

weight reduction in a primary care setting. BMC Family

Practice 2005;6(1):5.

Luque CA, Rey JA. Sibutramine; a serotonin norepinephrine

reuptake inhibitor for the treatment of obesity. Ann

Pharmacother 1999;33:968–78.

Iqbal F, Naz R. Patterns of diabetes mellitus in Pakistan: An

overview of problems. Pak J Med Res 2005;44(1):59–64.

Wooltorton E. Obesity drug sibutramine (Meridia):

hypertension and cardiac arrhythmias. CMAJ